Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia

Yasuo Tohmiya, Yoshio Koide, Shinichi Fujimaki, Hideo Harigae, Tadao Funato, Mitsuo Kaku, Tomonori Ishii, Yasuhiko Munakata, Junichi Kameoka, Takeshi Sasaki

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Stanniocalcin is a glycoprotein hormone that regulates the calcium level in fish. We found that mRNA of human stanniocalcin 1 (STC-1) is detectable in phytohemagglutinin-stimulated T cells and in most human leukemia cell lines, suggesting a role of STC-1 for cell proliferation. This finding prompts us to study the usefulness of STC-1 for monitoring acute leukemia. The levels of STC-1 transcripts increased in patients with acute leukemia at diagnosis and relapse, as judged by quantitative real-time RT-PCR. Levels of transcripts rapidly decreased to within the cut-off levels, when the blast numbers decreased with chemotherapy. Prolonged elevation of STC-1 levels after treatment was associated with a poor prognosis. All of 7 patients relapsed 1 to 4 months after they showed an elevated level of the transcripts in clinical remission. These results indicate that STC-1 is a novel marker or minimal residual disease of acute leukemia, and for an early diagnosis of relapse.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalTohoku Journal of Experimental Medicine
Issue number2
Publication statusPublished - 2004 Oct


  • Leukemia
  • Minimal residual disease (MRD)
  • Real-time PCR
  • Stanniocalcin 1 (STC-1)


Dive into the research topics of 'Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia'. Together they form a unique fingerprint.

Cite this